Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HER1, YOR227W
50 results:

  • 1. Assessment of her1 (rs11543848) and HER2 (rs1136201) polymorphism and their association with colorectal cancer susceptibility in Khyber Pakhtunkhwa, Pakistan.
    Ullah A; Khan BM; Khan NU; Muntaha ST; Khan S; Khan AU; Almutairi MH; Ali I
    Mol Biol Rep; 2023 Dec; 51(1):1. PubMed ID: 38040921
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Based on lapatinib innovative near-infrared fluorescent probes targeting her1/HER2 for in vivo tumors imaging.
    Li C; Lin Q; Hu F; Bao R; Cai H; Gu Y
    Biosens Bioelectron; 2022 Oct; 214():114503. PubMed ID: 35779413
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in colorectal cancer.
    Rau A; Janssen N; Kühl L; Sell T; Kalmykova S; Mürdter TE; Dahlke MH; Sers C; Morkel M; Schwab M; Kontermann RE; Olayioye MA
    Mol Cancer Ther; 2022 May; 21(5):799-809. PubMed ID: 35247930
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
    Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
    Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of 6 Hub Proteins and Protein Risk Signature of colorectal cancer.
    Yue T; Liu C; Zhu J; Huang Z; Guo S; Zhang Y; Xu H; Liu Y; Wang P; Chen S
    Biomed Res Int; 2020; 2020():6135060. PubMed ID: 33376727
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line.
    Antognelli C; Palumbo I; Piattoni S; Calzuola M; Del Papa B; Talesa VN; Aristei C
    Int J Radiat Biol; 2020 Nov; 96(11):1504-1512. PubMed ID: 32910714
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Exploration of a F(ab')
    Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
    Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Radiolabeled F(ab')
    Bellaye PS; Moreau M; Raguin O; Oudot A; Bernhard C; Vrigneaud JM; Dumont L; Vandroux D; Denat F; Cochet A; Brunotte F; Collin B
    Clin Transl Oncol; 2018 Dec; 20(12):1557-1570. PubMed ID: 29777377
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced colorectal cancer.
    Seligmann JF; Hatch AJ; Richman SD; Elliott F; Jacobs B; Brown S; Hurwitz H; Barrett JH; Quirke P; Nixon AB; Seymour MT
    JAMA Oncol; 2018 Apr; 4(4):564-568. PubMed ID: 29075780
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Neratinib: First Global Approval.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1695-1704. PubMed ID: 28884417
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. HER family receptor expression and prognosis in pancreatic cancer.
    Bittoni A; Mandolesi A; Andrikou K; Santoni M; Alfonsi S; Lanese A; Loretelli C; Pellei C; Piva F; Scarpelli M; Cascinu S
    Int J Biol Markers; 2015 Jul; 30(3):e327-32. PubMed ID: 26109364
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
    Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
    PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Epidermal growth factor receptor inhibitors: coming of age.
    Mahipal A; Kothari N; Gupta S
    Cancer Control; 2014 Jan; 21(1):74-9. PubMed ID: 24357745
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
    Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
    J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for her1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract] [Full Text] [Related]  


    of 3.